BRAF and thyroid cancer: In addition, we demonstrated that, although NG2 did not affect tumor growth in vitro and in vivo, it decreased the sensitivity of BRAF-mutant thyroid cancer cells to BRAF inhibitor by regulating the activities of several major RTKs.